Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7683 | FAK Inhibitor 14 |
| Selective focal adhesion kinase (FAK) inhibitor that displays no significant activity at a range of other kinases including EGFR, PDGFR and IGF-RI. Prevents FAK autophosphorylation at Y397 (IC50 = 1 μM), promotes cell detachment and inhibits cell adhesion in vitro. Exhibits antiproliferative activity in a variety of human tumor cell lines in vitro and in breast cancer cells in vivo. | |
| BCC7688 | GSK 0660 |
| Selective PPARδ antagonist (IC50 values are 0.155, > 10 and ≥ 10 μM at PPARδ, PPARα and PPARγ respectively). Exhibits inverse agonist effects when administered by itself. | |
| BCC7692 | UCPH 101 |
| Selective non-substrate inhibitor of EAAT1 (IC50 values are 660, >300000 and >300000 nM for EAAT1, EAAT2 and EAAT3 respectively). Also demonstrates no significant inhibition at EAAT4 or EAAT5 in a patch-clamp electrophysiology assay (at final concentration up to 10 μM). | |
| BCC7693 | Cyclosomatostatin |
| Non-selective somatostatin (sst) receptor antagonist. Blocks the effects of sst on airway β-adrenergic function, CRF-induced suppression of gastric empyting, modulation of ACh release and growth hormone, insulin and glucagon release. Reported to act as an sst receptor agonist in human neuroblastoma cell line SH-SY5Y. | |
| BCC7695 | ML 10302 hydrochloride |
| Potent 5-HT4 partial agonist (EC50 = 4 nM) that displays > 680-fold selectivity over 5-HT3 receptors (Ki values are 1.07 and 730 nM respectively). Increases sAPPα levels in the cortex in an animal model of Alzheimer's disease and exhibits progastrokinetic effects in vivo. | |
| BCC7696 | LG 101506 |
| Selective RXR modulator (Ki values are 3, 9 and 11 for RXRα, RXRβ and RXRγ respectively). Displays poor binding affinity for RAR isoforms (Ki values are 2746, 3516 and >10,000 nM for RARα, RARβ and RARγ respectively). Binding to RXR results in selective activation of RXR:PPARγ, RXR:PPARα and RXR:PPARδ heterodimers. | |
| BCC7697 | BMS 493 |
| Pan-retinoic acid receptor (pan-RAR) inverse agonist. Enhances nuclear corepressor (NCoR) interaction with RARs. Binding induces analogous conformational changes in all RAR types (RARα, RARβ and RARγ). | |
| BCC7700 | S 24795 |
| Partial agonist of α7 nAChR. Improves mnemonic function in aged mice for the treatment of aging-related memory disturbances. Displays more efficient memory-enhancing effects than memantine in Alzheimer's disease mouse models. | |
